WallStreetZenWallStreetZen

NASDAQ: EFTR
Effector Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for EFTR

Based on 1 analyst offering 12 month price targets for Effector Therapeutics Inc.
Min Forecast
$24.00+1,311.76%
Avg Forecast
$24.00+1,311.76%
Max Forecast
$24.00+1,311.76%

Should I buy or sell EFTR stock?

Based on 1 analyst offering ratings for Effector Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EFTR stock forecasts and price targets.

EFTR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-28

1 of 1

Forecast return on equity

Is EFTR forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is EFTR forecast to generate an efficient return on assets?

EFTR revenue forecast

What is EFTR's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$2.2M

EFTR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EFTR$1.70$24.00+1,311.76%Buy
ENVB$0.88$10.00+1,035.07%Buy
CVKD$0.40$3.50+770.65%Buy
TRVN$0.35$9.00+2,456.82%Buy
XBIO$4.20N/AN/A
View Top Biotech Stocks

Effector Therapeutics Stock Forecast FAQ

Is Effector Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: EFTR) stock is to Buy EFTR stock.

Out of 1 analyst, 0 (0%) are recommending EFTR as a Strong Buy, 1 (100%) are recommending EFTR as a Buy, 0 (0%) are recommending EFTR as a Hold, 0 (0%) are recommending EFTR as a Sell, and 0 (0%) are recommending EFTR as a Strong Sell.

If you're new to stock investing, here's how to buy Effector Therapeutics stock.

What is EFTR's revenue growth forecast for 2025-2025?

(NASDAQ: EFTR) Effector Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 249.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.2%.

Effector Therapeutics's revenue in 2024 is $0.

In 2025, EFTR is forecast to generate $8,112,080 in revenue, with the lowest revenue forecast at $8,112,080 and the highest revenue forecast at $8,112,080.

What is EFTR's forecast return on assets (ROA) for 2025-2025?

(NASDAQ: EFTR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.83%.

What is EFTR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EFTR price target, the average EFTR price target is $24.00, with the highest EFTR stock price forecast at $24.00 and the lowest EFTR stock price forecast at $24.00.

The Wall Street analyst predicted that Effector Therapeutics's share price could reach $24.00 by Mar 28, 2025. The average Effector Therapeutics stock price prediction forecasts a potential upside of 1,311.76% from the current EFTR share price of $1.70.

What is EFTR's forecast return on equity (ROE) for 2025-2025?

(NASDAQ: EFTR) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.